Reporting on Adverse Clinical Events
Clin-Alert · 2026-06 · 64 (11-12) · 1-21
DOI: 10.1177/00694770261456084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clin-Alert, online erschienen am 09.06.2026.
Abstract (Originalsprache)
An observational comparative study using data from a medico-administrative database evaluated the risk of congenital anomalies associated with the use of beta-blockers during the first trimester of pregnancy. The use of beta-blockers during the first trimester of pregnancy (n = 1813) was compared with women receiving calcium channel blockers (n = 2903) and with women unexposed to antihypertensive medications (n = 172 284). Multivariate analyses demonstrated a statistically significant increased risk of major congenital anomalies in fetuses/children exposed to in utero beta-blockers (adjusted odds ratio [aOR]: 1.56; 95% CI: 1.07-2.18) compared with unexposed group. In contrast, there was not an observed increased risk when beta-blocker use was compared with calcium channel blockers (aOR: 0.71; 95% CI: 0.29-2.15). Based on the results from this observational comparative study, the authors concluded that the use of beta-blockers during the first trimester of pregnancy is not associated with a risk of major congenital anomalies when compared with the use of calcium channel blockers. However, an increased risk was associated when beta-blocker use was compared with non-exposure to anti-hypertensive medications. Beta-blockers [Labetolol, Propranolol, Metoprolol]
Zitieren
APA
(2026). Reporting on Adverse Clinical Events. Clin-Alert, 64(11-12), 1-21. https://doi.org/10.1177/00694770261456084
Vancouver
Reporting on Adverse Clinical Events. Clin-Alert. 2026;64(11-12):1-21. doi:10.1177/00694770261456084
BibTeX
@article{euvimed2026,
title = {Reporting on Adverse Clinical Events},
journal = {Clin-Alert},
year = {2026},
volume = {64},
number = {11-12},
pages = {1--21},
doi = {10.1177/00694770261456084}
}
EUVIMED